Adherium Brings In MicroDose Co-Founder As Senior VP
SmartInhaler developer Adherium has appointed the co-founder of MicroDose Therapeutx to head up its European base in Amsterdam, Netherlands.
You may also be interested in...
Developer of the SmartInhaler, Adherium Ltd, has established a European subsidiary which will be headed by John Tarplee, a veteran of the pharmaceutical industry with over 30 years’ experience. As Senior Vice-President Business development, Europe, Tarplee will lead market development and partnering activities in that region.
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?